Trials / Recruiting
RecruitingNCT07408336
Clinical Study of AFN50 Injection in the Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- AlphaNa Bioscience Company Limited · Academic / Other
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated trial designed to evaluate the safety, tolerability and primary efficacy of AFN50 injection for the treatment of autoimmune diseases.
Detailed description
This study is a prospective exploratory clinical trial in subjects with autoimmune diseases, mainly relapsing and refractory systemic lupus erythematosus. The objective is to evaluate the safety, tolerability, and primary efficacy of AFN50 injection in relapsing and refractory systemic lupus erythematosus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFN50 injection | Intravenous infusion therapy. AFN50 was developed using novel T-cell-targeted lipid nanoparticles (T-LNP) encapsulating mRNA encoding Chimeric Antigen Receptor. |
Timeline
- Start date
- 2026-02-04
- Primary completion
- 2028-02-04
- Completion
- 2029-02-03
- First posted
- 2026-02-13
- Last updated
- 2026-03-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07408336. Inclusion in this directory is not an endorsement.